Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

r the remaining 30% of the principal, or $5.1 million. The remaining $5.0 million in outstanding convertible notes matured on July 15, 2009. In accordance with the terms of the notes, the company elected to pay 50% of the principal plus accrued and unpaid interest, or $2.6 million, in cash and issued 1,016,939 shares of common stock to pay the remaining $2.6 million of the principal plus accrued and unpaid interest.
  • Entered into an initial agreement to license the company's Seasonal and Pandemic Influenza VLP technology to ROVI to create a comprehensive influenza vaccine solution including a facility for the Spanish government using our proprietary, recombinant VLP vaccine technology. A non-profit foundation, jointly sponsored by ROVI and the Spanish authorities, will be formed and funded to support Phase III clinical development and other studies necessary to achieve market authorization of the VLP-based influenza vaccines in the European Union, which is targeted for 2012.
  • Raised $21.9 million from the sale of 7.4 million shares of common stock through the ATM program.
  • Launched CPL Biologicals Pvt. Ltd, the previously announced joint venture with Cadila Pharmaceuticals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.
  • Recruited key executives to support the future growth of the company. New appointments include Mr. John Trizzino as Senior Vice President, International and Governmental Affairs, and Mr. Fredrick W. Driscoll as Vice President, Chief Financial Officer and Treasurer.
  • Achieved a major production milestone in the Pandemic H1N1 influenza program by manufacturing a cGMP-quality batch of the company's VLP vaccine candidate against this virus within 11 weeks of receiving the genetic sequence of the pandemic virus strain from the Centers of Disease Control.
  • "Our progress since the first quarter has been transfor
    '/>"/>

    SOURCE Novavax, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
    2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
    3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
    4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
    5. Novavax Announces Repayment of $5 Million of Convertible Debt
    6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
    7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
    8. Novavax Appoints Stanley Erck to Board of Directors
    9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
    10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
    11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... 2014 Today, TiFiber, Inc. ... production facility and future company headquarters in Fort ... new materials that safely and effectively control dangerous ... of its historic, strong support for manufacturing, but ... leading edge, technology-based companies such as TiFiber. ...
    (Date:12/19/2014)... Biddeford, ME (PRWEB) December 18, 2014 ... founding director of the Center for Excellence in the ... of New England, has been selected as a member ... He is the first neuroscientist from Maine to receive ... a nonprofit organization supported entirely by the Dana Foundation. ...
    (Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
    (Date:12/19/2014)... (PRWEB) December 19, 2014 The ... to the rising ageing population and technological innovations ... and nutraceutical industries are catalysing the growth of ... @ http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report ... as well as new entrants/smaller firms to gauge ...
    Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4
    ... Stock Exchange Symbol: MS, EDMONTON, April 15 /PRNewswire-FirstCall/ ... the treatment of multiple sclerosis (MS), today,announced that Mr. ... EQUITIES Magazine,s 57th Anniversary Spring Conference., WHEN: ... AM (Eastern Time), WHERE: The ...
    ... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) presented abstract #4844 ... Cancer Research (AACR) in San Diego. The poster,entitled "SGX523, ... tyrosine kinase (MET), inhibits growth of human glioblastoma,tumors in ... session,entitled Small Molecule Kinase Inhibitors 1 in Exhibit Hall ...
    ... Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... to $185 million in exchange for rights to ... sales of Lexiscan(TM),(regadenoson) injection. CV Therapeutics received $175 ... a potential future milestone payment,of $10 million., ...
    Cached Biology Technology:BioMS Medical to present at EQUITIES Conference 2SGX Presents Preclinical MET Data at AACR 2SGX Presents Preclinical MET Data at AACR 3CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3
    (Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
    (Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
    (Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
    Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
    ... HOUSTON (Nov. 8, 2012) Four young scientists ... Research Institute (NSBRI). Through this two-year program, they conduct ... during long-duration spaceflights. In addition to receiving mentorship from ... are members of one of NSBRI,s seven research teams. ...
    ... in removing the extra copy of chromosome 21 in ... In Down syndrome, the body,s cells contain three ... A triplicate of any chromosome is a serious ... one-quarter of pregnancy loss from spontaneous miscarriages, according to ...
    ... 2012  Genomic Health, Inc. (Nasdaq: GHDX ) today ... Officer, Chairman and President will present at the following conferences ... on Thursday, November 15, 2012 at 2:00 p.m. Mountain Time ... Jaffray Healthcare Conference on Tuesday, November 27 at 2:30 p.m. ...
    Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2Extra chromosome 21 removed from Down syndrome cell line 2Extra chromosome 21 removed from Down syndrome cell line 3Genomic Health to Present at Two Upcoming Investor Conferences 2Genomic Health to Present at Two Upcoming Investor Conferences 3
    HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Rad51, N-terminal...
    Phospho-mu-Opioid Receptor (Ser375) Antibody...
    Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
    Biology Products: